Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders

Irene M. Ghobrial, Thomas M. Habermann, Matthew J. Maurer, Susan M. Geyer, Kay M. Ristow, Timothy S. Larson, Randall C. Walker, Stephen M. Ansell, William R. Macon, Gregory G. Gores, Mark D. Stegall, Christopher G. McGregor

Research output: Contribution to journalArticle

115 Scopus citations

Abstract

Purpose: The objective of this study was to determine prognostic factors for overall survival in patients with post-transplantation lymphoproliferative disorders (PTLDs). Patients and Methods: This study focused on the 107 adult solid organ transplantation patients who were diagnosed with PTLDs at Mayo Clinic (Rochester, MN) between December 1970 and May 2003. Results: The median age at the time of diagnosis was 48 years (range, 15 to 75 years). Extranodal disease including grafted organ involvement was present in 85 patients (80%). The graft organ was involved in 30 patients (28%). At the time of these analyses, 62 patients (58%) had died. The median survival for the entire cohort was 31.5 months (95% CI, 10.7 to 72.5 months). The median follow-up of living patients was 51.8 months (range, 5.6 to 202.6 months). In univariate analyses for overall survival from the time of PTLD diagnosis, the following poor prognostic factors were identified: poor performance status with Eastern Cooperative Oncology Group levels 3 and 4 (P < .0001), grafted organ involvement (P = .0005), the presence of one or more extranodal sites (P = .005), both nodal and extranodal disease (P = .002), high International Prognostic Index (P = .006), advanced stage (P = .001), and elevated lactate dehydrogenase (P = .03). A final multivariable model for survival was constructed using three factors: poor performance status (3 to 4), monomorphic disease, and graft organ involvement. Conclusion: A prognostic model has been developed for PTLD patients using one center's 30 years of experience. We propose additional confirmation and validation of these prognostic factors in larger prospective studies.

Original languageEnglish (US)
Pages (from-to)7574-7582
Number of pages9
JournalJournal of Clinical Oncology
Volume23
Issue number30
DOIs
StatePublished - Dec 1 2005

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this